Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), ...

The European Organisation for Research and Treatment of Cancer (EORTC) has recently produced guidelines for the use of G-CSF in adults with lymphomas and solid tumors undergoing chemotherapy.